Advance for clinical pharmacology of the direct renin inhibitor aliskiren
10.3969/j.issn.1001-6821.2010.03.018
- VernacularTitle:新型口服抗高血压药阿利克伦的临床药理学研究进展
- Author:
Min-Chun JI
1
;
Qing-Qing QIAN
;
Wei QIAN
;
Yao-Fang YANG
Author Information
1. 复旦大学附属上海市第五人民医院
- Keywords:
renin inhibitor;
aliskiren;
antihypertensive agent
- From:
The Chinese Journal of Clinical Pharmacology
2010;26(3):236-240
- CountryChina
- Language:Chinese
-
Abstract:
The oral direct renin inhibitor aliskiren is a novel , safe and ef-fective antihypertensive agent, it has renoprotection and reduces left ven-tricular mass. Aliskiren can be used as monotherapy or in combination with angiotensin converting enzyme inhibitors (ramipril), angiotensin re-ceptor blockers (valsartan) and hydrochlorothiazide diuretics in patients with hypertension. It has dose-dependent antihypertensive effect and good tolerability of patients.
